Back

NNV024, a novel humanized anti-CD37 antibody with enhanced ADCC and prolonged plasma half-life in human FcRn transgenic mice for treatment of NHL

Generaloc, R.; Fiorito, E.; Foss, S.; Pascal, V.; Heyerdahl, H.; Repetto, A.; Andersen, J. T.; Tjonnfjord, G.; Skanland, S. S.; Dahle, J.

2023-07-12 cancer biology
10.1101/2023.07.12.548667 bioRxiv
Show abstract

There is an unmet medical need for new therapeutic approaches and targets for patients with non- Hodgkin lymphoma (NHL) who relapse or are refractory to anti-CD20 immunotherapy. Therefore, we developed a humanized IgG1 antibody targeting CD37, which was tailored to be afucosylated for enhanced antibody-dependent cellular cytotoxicity (ADCC) (NNV024). In line with this, NNV024 induced three-fold more potent ADCC activity against patient-derived chronic lymphocytic leukemia (CLL) cells compared with anti-CD20 obinutuzumab. Moreover, NNV024 showed 2-fold higher ADCC activity than anti-CD20 rituximab and a recombinant version of DuoHexaBody-CD37 against both NHL and CLL cells. Survival was significantly longer after NNV024 treatment than with obinutuzumab in a mouse model. In addition, NNV024 showed a favourable plasma half-life in human FcRn transgenic mice of about 9-days, which was 2-fold longer than that of obinutuzumab and DuoHexaBody-CD37. These results warrant the further development of NNV024 as a treatment for NHL.

Matching journals

The top 9 journals account for 50% of the predicted probability mass.

1
Frontiers in Immunology
○ 638 papers in training set
Top 0.8%
12.8%
Similar papers in this journal
2
Antibody Therapeutics
◐ 16 papers in training set
Top 0.1%
8.0%
Similar papers in this journal
3
PLOS ONE
● 5266 papers in training set
Top 23%
6.8%
Similar papers in this journal
4
OncoImmunology
○ 24 papers in training set
Top 0.1%
5.5%
Similar papers in this journal
5
mAbs
○ 32 papers in training set
Top 0.1%
4.5%
Similar papers in this journal
6
Molecular Cancer Therapeutics
● 40 papers in training set
Top 0.2%
4.4%
7
Scientific Reports
○ 3612 papers in training set
Top 28%
3.5%
8
Frontiers in Oncology
○ 103 papers in training set
Top 1%
3.4%
9
Antiviral Research
○ 50 papers in training set
Top 0.2%
3.3%
50% of probability mass above
10
Journal for ImmunoTherapy of Cancer
● 75 papers in training set
Top 0.9%
2.4%
11
Leukemia
○ 42 papers in training set
Top 0.4%
2.1%
12
eBioMedicine
○ 183 papers in training set
Top 3%
1.5%
13
International Journal of Molecular Sciences
○ 494 papers in training set
Top 11%
1.1%
14
Blood
● 74 papers in training set
Top 1.0%
1.1%
15
Blood Advances
● 62 papers in training set
Top 0.9%
1.1%
16
Cancers
○ 213 papers in training set
Top 4%
1.1%
17
Communications Biology
○ 993 papers in training set
Top 20%
1.1%
18
British Journal of Cancer
○ 49 papers in training set
Top 1%
1.1%
19
Journal of Immunological Methods
○ 24 papers in training set
Top 0.2%
1.1%
20
JCI Insight
● 277 papers in training set
Top 6%
1.1%
21
Nature Communications
○ 5641 papers in training set
Top 50%
1.1%
22
ACS Pharmacology & Translational Science
● 40 papers in training set
Top 0.6%
1.1%
23
Proceedings of the National Academy of Sciences
● 2444 papers in training set
Top 37%
1.0%
24
Clinical Chemistry and Laboratory Medicine (CCLM)
○ 13 papers in training set
Top 0.1%
1.0%
25
Cancer Immunology, Immunotherapy
○ 12 papers in training set
Top 0.2%
0.9%
26
Blood Cancer Journal
○ 14 papers in training set
Top 0.3%
0.9%
27
Science Advances
● 1243 papers in training set
Top 30%
0.9%
28
Cell Communication and Signaling
○ 51 papers in training set
Top 1%
0.9%
29
EMBO Molecular Medicine
○ 95 papers in training set
Top 2%
0.9%
30
eLife
● 5828 papers in training set
Top 66%
0.9%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.